ClinicalTrials.gg
CompletedNCT02914379Updated Aug 25, 2023Results posted

A Study of LY3337641 in Healthy Male Participants

A Phase 1 interventional study of [¹⁴C]-LY3337641 in Healthy, sponsored by Eli Lilly and Company. Completed at 1 site in United States. Open to male participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2023-08-25.

Sponsored by Eli Lilly and Company · Phase 1, Interventional, and Basic science

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
6
Allocation
Not applicable
Ages
18 Years to 65 Years
Sex
Male
01

Study summary

The purpose of this study is to measure how much LY3337641 gets into the bloodstream and how long it takes the body to get rid of it. In addition, the safety and tolerability of the study drug will be evaluated.

Participants will be admitted to a clinical research unit (CRU) the day before dosing. Participants remain confined to the CRU for at least 7 days. Participants may be discharged from the CRU any time after 7 days post-dose (Day 8), and up to a maximum of 21 days post-dose (Day 22).

This study will last approximately 30 days for each participant, not including screening. Screening is required within 28 days prior to the start of the study.

02

Conditions studied

  • Healthy
03

In context

Lead sponsor

Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.

Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Overtly healthy males, as determined by medical history and physical examination
  • Have a (BMI) between 18.5 and 32.0 kilograms per meter squared (kg/m²)
  • Have clinical laboratory test results within normal reference range for the population or investigative site, or results with acceptable deviations that are judged to be not by the investigator
  • Have venous access sufficient to allow for blood sampling as per the protocol
  • Are able and willing to give signed
  • Generally have a minimum of 1 bowel movement per day

Exclusion criteria

Exclusion Criteria:

  • Have participated, within the last 30 days, in a clinical trial involving an product. If the previous investigational product has a long half-life, 3 months or 5 half-lives (whichever is longer, if known) should have passed
  • Have a significant history of or current cardiovascular, respiratory, hepatic, renal, gastrointestinal (GI) (cholecystectomy not acceptable), endocrine, hematological, dermatologic, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs; of constituting a risk when taking the investigational product; or of interfering with the interpretation of data
  • Regularly use known drugs of abuse and/or show positive findings on urinary drug screening
  • Have used or intend to use over-the-counter or prescription medication, including herbal medications, within 14 days prior to dosing
  • Have donated blood of more than 500 milliliter (mL) within the month prior to screening
  • Have an average weekly alcohol intake that exceeds 21 units per week, and are unwilling to stop alcohol consumption for 48 hours prior to admission, and while resident in the clinical research unit (CRU)
  • In the opinion of the investigator or sponsor, are unsuitable for inclusion in the study
  • Have had exposure to significant diagnostic, therapeutic, or employment related radiation within 12 months prior to dosing (serial x-ray or computed tomography scans, barium meal, current employment in a job requiring radiation exposure monitoring)
  • Have participated in a [¹⁴C] study within the last 6 months prior to admission for this study. The total 12-month exposure from this study and a maximum of one other previous [¹⁴C]-study within 6 to 12 months of this study must be within the Code of Federal Regulations (CFR) recommended levels considered safe (per 21 CFR 361.1): less than 5000 Milli-rem (mrem) /year whole body annual exposure
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
6 participants (actual)

Study arms

  • Experimental
    20mg [¹⁴C]-LY3337641

    Participants received 20 milligrams (mg) oral dose of LY3337641 containing 120 microcuries of radioactivity.

    Drug: [¹⁴C]-LY3337641

Interventions

06

What researchers measure

Primary outcomes

  1. Urinary Excretion of Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered

    Urinary excretion samples from each participant were measured by liquid scintillation counting. The radioactive counts detected in urine samples were each divided by the theoretical radioactive count in the total radioactive dose administered and multiplied by 100% to arrive at a percentage of total radioactive dose excreted in urine and feces.

    Time frame: Baseline up to 22 days

  2. Fecal Excretion of Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered

    Fecal excretion samples from each participant were measured by liquid scintillation counting. The radioactive counts detected in fecal samples were each divided by the theoretical radioactive count in the total radioactive dose administered and multiplied by 100% to arrive at a percentage of total radioactive dose excreted in feces.

    Time frame: Baseline up to 22 days

Secondary outcomes

  1. Pharmacokinetics: Maximum Observed Concentration (Cmax) of Plasma LY3337641

    Time frame: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72, 96, 120, 144, 168, 216, 264 and 312 hours post dose

  2. Pharmacokinetics: Maximum Observed Concentration (Cmax) of Plasma Radioactivity

    Time frame: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72, 96, 120, 144, 168, 216, 264 and 312 hours post dose

  3. Pharmacokinetics: Maximum Observed Concentration (Cmax) of Whole Blood Radioactivity

    Time frame: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72, 96, 120, 144, 168, 216, 264 and 312 hours post dose

  4. Pharmacokinetics: Area Under the Concentration-Time Curve From Time Zero to Infinity (AUC 0 to ∞) of Plasma LY3337641

    Time frame: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72, 96, 120, 144, 168, 216, 264 and 312 hours post dose

  5. Pharmacokinetics: Area Under the Concentration-Time Curve From Time Zero to Infinity (AUC 0 to ∞) of Plasma Radioactivity

    Time frame: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72, 96, 120, 144, 168, 216, 264 and 312 hours post dose

  6. Pharmacokinetics: Area Under the Concentration-Time Curve From Time Zero to Infinity (AUC 0 to ∞) of Whole Blood Radioactivity

    Time frame: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72, 96, 120, 144, 168, 216, 264 and 312 hours post dose

  7. Pharmacokinetics: Total Number of Measurable Metabolites of LY3337641 in Plasma, Urine and Feces

    Time frame: Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72, 96, 120, 144, 168, 216, 264, and 312 hours postdose

07

Results

Posted Aug 25, 2023

Participant flow

Participant flow — Overall Study
Milestone20mg [¹⁴C]-LY3337641
Started6
Completed6
Not completed0

Outcome measures

PrimaryUrinary Excretion of Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered

Urinary excretion samples from each participant were measured by liquid scintillation counting. The radioactive counts detected in urine samples were each divided by the theoretical radioactive count in the total radioactive dose administered and multiplied by 100% to arrive at a percentage of total radioactive dose excreted in urine and feces.

Time frame:
Baseline up to 22 days
Reported as:
Mean · Percentage of total dose
Urinary Excretion of Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered
Percentage of total dose20 mg [¹⁴C]-LY3337641
Urinary Excretion of Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered2.9 ± 1.0
PrimaryFecal Excretion of Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered

Fecal excretion samples from each participant were measured by liquid scintillation counting. The radioactive counts detected in fecal samples were each divided by the theoretical radioactive count in the total radioactive dose administered and multiplied by 100% to arrive at a percentage of total radioactive dose excreted in feces.

Time frame:
Baseline up to 22 days
Reported as:
Mean · Percentage of total dose
Fecal Excretion of Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered
Percentage of total dose20 mg [¹⁴C]-LY3337641
Fecal Excretion of Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose Administered86.4 ± 5.1
SecondaryPharmacokinetics: Maximum Observed Concentration (Cmax) of Plasma LY3337641
Time frame:
Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72, 96, 120, 144, 168, 216, 264 and 312 hours post dose
Reported as:
Geometric mean · Nanograms/milliliter (ng/mL)
Pharmacokinetics: Maximum Observed Concentration (Cmax) of Plasma LY3337641
Nanograms/milliliter (ng/mL)20 mg [¹⁴C]-LY3337641
Pharmacokinetics: Maximum Observed Concentration (Cmax) of Plasma LY333764177.9 ± 26
SecondaryPharmacokinetics: Maximum Observed Concentration (Cmax) of Plasma Radioactivity
Time frame:
Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72, 96, 120, 144, 168, 216, 264 and 312 hours post dose
Reported as:
Geometric mean · nanogram equivalents/g (ng-equiv/g)
Pharmacokinetics: Maximum Observed Concentration (Cmax) of Plasma Radioactivity
nanogram equivalents/g (ng-equiv/g)20 mg [¹⁴C]-LY3337641
Pharmacokinetics: Maximum Observed Concentration (Cmax) of Plasma Radioactivity122 ± 25
SecondaryPharmacokinetics: Maximum Observed Concentration (Cmax) of Whole Blood Radioactivity
Time frame:
Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72, 96, 120, 144, 168, 216, 264 and 312 hours post dose
Reported as:
Geometric mean · ng/mL
Pharmacokinetics: Maximum Observed Concentration (Cmax) of Whole Blood Radioactivity
ng/mL20 mg [¹⁴C]-LY3337641
Pharmacokinetics: Maximum Observed Concentration (Cmax) of Whole Blood Radioactivity67.5 ± 24
SecondaryPharmacokinetics: Area Under the Concentration-Time Curve From Time Zero to Infinity (AUC 0 to ∞) of Plasma LY3337641
Time frame:
Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72, 96, 120, 144, 168, 216, 264 and 312 hours post dose
Reported as:
Geometric mean · Nanograms*hours per milliliter (ng*h/mL)
Pharmacokinetics: Area Under the Concentration-Time Curve From Time Zero to Infinity (AUC 0 to ∞) of Plasma LY3337641
Nanograms*hours per milliliter (ng*h/mL)20 mg [¹⁴C]-LY3337641
Pharmacokinetics: Area Under the Concentration-Time Curve From Time Zero to Infinity (AUC 0 to ∞) of Plasma LY3337641370 ± 25
SecondaryPharmacokinetics: Area Under the Concentration-Time Curve From Time Zero to Infinity (AUC 0 to ∞) of Plasma Radioactivity
Time frame:
Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72, 96, 120, 144, 168, 216, 264 and 312 hours post dose
Reported as:
Geometric mean · ng-equivalents*h/gram (ng-equiv*h/g)
Pharmacokinetics: Area Under the Concentration-Time Curve From Time Zero to Infinity (AUC 0 to ∞) of Plasma Radioactivity
ng-equivalents*h/gram (ng-equiv*h/g)20 mg [¹⁴C]-LY3337641
Pharmacokinetics: Area Under the Concentration-Time Curve From Time Zero to Infinity (AUC 0 to ∞) of Plasma Radioactivity1240 ± 51
SecondaryPharmacokinetics: Area Under the Concentration-Time Curve From Time Zero to Infinity (AUC 0 to ∞) of Whole Blood Radioactivity
Time frame:
Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72, 96, 120, 144, 168, 216, 264 and 312 hours post dose
Reported as:
Geometric mean · ng*h/mL
Pharmacokinetics: Area Under the Concentration-Time Curve From Time Zero to Infinity (AUC 0 to ∞) of Whole Blood Radioactivity
ng*h/mL20 mg [¹⁴C]-LY3337641
Pharmacokinetics: Area Under the Concentration-Time Curve From Time Zero to Infinity (AUC 0 to ∞) of Whole Blood Radioactivity5840 ± 105
SecondaryPharmacokinetics: Total Number of Measurable Metabolites of LY3337641 in Plasma, Urine and Feces
Time frame:
Predose, 0.5, 1, 2, 3, 4, 6, 8, 10, 12, 16, 24, 36, 48, 72, 96, 120, 144, 168, 216, 264, and 312 hours postdose
Reported as:
Number · Number of Metabolites
Pharmacokinetics: Total Number of Measurable Metabolites of LY3337641 in Plasma, Urine and Feces
Number of Metabolites20 mg [¹⁴C]-LY3337641
Plasma6
Urine4
Feces8

Adverse events

Collected over From Baseline to End of Study (Up to 29 Days). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
20 mg [¹⁴C]-LY33376410/6 (0%)0/6 (0%)1/6 (16.7%)
Most frequent other events
Most frequent other events
Event20 mg [¹⁴C]-LY3337641
Abdominal discomfortGastrointestinal disorders1/6
Change of bowel habitGastrointestinal disorders1/6
DiarrhoeaGastrointestinal disorders1/6
EcchymosisSkin and subcutaneous tissue disorders1/6

Baseline characteristics

Age, Continuous
Age, Continuous(Years)20mg [¹⁴C]-LY3337641
Mean34.3 ± 11.4
Sex: Female, Male
Sex: Female, Male(Participants)20mg [¹⁴C]-LY3337641
Female0
Male6
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)20mg [¹⁴C]-LY3337641
Hispanic or Latino0
Not Hispanic or Latino6
Unknown or Not Reported0
Race (NIH/OMB)
Race (NIH/OMB)(Participants)20mg [¹⁴C]-LY3337641
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American1
White5
More than one race0
Unknown or Not Reported0
Region of Enrollment
Region of Enrollment(Participants)20mg [¹⁴C]-LY3337641
United States6
08

Study locations

1 site
  • Covance Clinical Research Unit
    Madison, Wisconsin 53704, United States
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2016, a primary completion of Nov 2016 and a completion of Nov 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2023, 6 years 9 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 21, 2016
First posted
Sep 26, 2016
Start
Sep 2016
Primary completionActual
Nov 2016
CompletionActual
Nov 2016
Results first posted
Aug 25, 2023
Last update
Aug 25, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 25, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02914379
Responsible party
Sponsor
First posted
Sep 26, 2016
Start date
Sep 2016
Primary completion
Nov 2016
Completion
Nov 2016
Results posted
Aug 25, 2023
Last update
Aug 25, 2023

Study contacts

Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
study director · Eli Lilly and Company

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Poseltinib

Start the discussion